Roots Analysis has done a detailed study on Artificial Intelligence in Oncology Market, 2022-2035, covering key aspects of the industry and identifying future growth opportunities.
Key Market Insights
§ Presently, more than 70+ industry players are engaged in the development of artificial intelligence in oncology- based software solutions in different regions of the globe; a relatively larger proportion of these players are small firms
§ The Artificial Intelligence in Oncology market is dominated by companies based in North America; of these majority were established post 2010. 52% of these provide AI in oncology- based software solutions to hospitals
§ It is worth highlighting that 26% of the players engaged in this domain are using both machine learning and deep learning technologies
§ The rising interest in this rapidly evolving domain can be validated by the partnerships inked in recent years; majority of the deals were signed for technology integration agreements.
§ Both established players and new entrants have forged several partnerships; 60% of the companies involved in technology integration agreements are mid- sized
§ In order to tap the lucrative opportunity, venture capital firms / strategic investors have actively supported the ongoing initiatives; over USD 5.9 billion has been invested across 99+ instances in the last 5 years
§ Over the past few years, there has been a steady increase in the patent activity within this domain, growing at a cumulative annualized growth rate of 31%
§ Approximately 2,770 patents have been filed within this domain; of which 1,608 patents have been filed in the US
§ The market opportunity associated with Artificial Intelligence in Oncology is anticipated to witness an annualized growth of over 54%, over the coming decade
Table of Contents
1. PREFACE
1.1. Overview
1.2. Scope of the Report
1.3. Market Segmentation
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1 Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Artificial Intelligence (AI)
3.3. Type Of AI
3.4. Applications of AI
3.5. Key Challenges Associated with Use of AI in Healthcare Sector
3.6. Future Perspectives
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. AI in Oncology: Market Landscape of Software providers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Type of End-User
4.2.6. Analysis by Year of Establishment, Company size and Location of Headquarters
4.3. AI in Oncology: Market Landscape of Software Solutions
4.3.1. Analysis by Type of Service(s) Offered
4.3.2. Analysis by Type of AI Technology Used
4.3.3. Analysis by Type of Platform
4.3.4. Analysis by Type of Service(s) Offered and Type of End-User
4.3.5. Analysis by Type of Platform and Type of AI Technology Used
4.3.6. Analysis by Type of Service(s) Offered, Location of Headquarters and Type of AI Technology Used
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Roche Diagnostics
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. AI Focused Service Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. IBM Watson Health
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. AI Focused Service Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. CancerCenter.AI
5.4.1. Company Overview
5.4.2. AI Focused Service Portfolio
5.4.3. Recent Development and Future Outlooks
5.5. GE Healthcare
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. AI Focused Service Portfolio
5.5.4. Recent Development and Future Outlook
5.6. Concert AI
5.6.1. Company Overview
5.6.2. AI Focused Service Portfolio
5.6.3. Recent Developments and Future Outlook
5.7. Path AI
5.7.1. Company Overview
5.7.2. AI Focused Service portfolio
5.7.3. Recent Development and Future Outlook
5.8. Berg
5.8.1. Company Overview
5.8.2. AI Focused Service Portfolio
5.8.3. Recent Development and Future Outlook
5.9. Median Technologies
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. AI Focused Service Portfolio
5.9.4. Recent Development and Future Outlook
5.10. iCAD
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. AI Focused Service Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. JLK Inspection
5.11.1. Company Overview
5.11.2. AI Focused Service Portfolio
5.11.3. Recent Development and Future Outlook
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. AI in Oncology Software providers: Company Competitiveness
6.4.1. Company Competitiveness: Small Companies in North America (Peer Group I)
6.4.2. Company Competitiveness: Small Companies in Europe (Peer Group II)
6.4.3. Company Competitiveness: Small Companies in Asia Pacific (Peer Group III)
6.4.4. Company Competitiveness: Mid-sized companies in North America (Peer Group IV)
6.4.5. Company Competitiveness: Mid-sized companies in Europe (Peer Group V)
6.4.6. Company Competitiveness: Mid-sized companies in Asia Pacific (Peer Group VI)
6.4.7. Company Competitiveness: Large companies in North America and Europe (Peer Group VII)
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. AI in Oncology: Patent Analysis
7.3.1. Analysis by Type of Patent
7.3.2. Analysis by Patent Publication Year
7.3.3. Analysis by Year-wise Trend of Filed Patent Applications and Granted Patents
7.3.4. Analysis by Geography
7.3.5. Analysis by Type of Industry
7.3.6. Analysis by Patent Age
7.3.7. Analysis by Legal Status
7.3.8. Analysis by CPC Symbols
7.3.9. Analysis by Top Applicants
7.3.10. Analysis by Key Inventors
7.4. AI in Oncology: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.4.2. AI in Oncology: Patent Valuation Analysis
8. PARTNERSHIPS
8.1. Chapter Overview
8.2. Partnership Models
8.3 AI in Oncology: Recent Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Distribution by Year and Type of Agreement
8.3.4. Distribution by Company Size and Type of Agreement
8.3.5. Distribution by Most Active Players and Type of Agreement
8.3.6. Analysis by Type of Cancer
8.3.7. Analysis by Type of Partner
8.3.8. Analysis by Year and Type of Partner
8.3.9. Intercontinental and Intracontinental Agreements
8.3.10. Local and International Agreements
8.3.11. Distribution by Country
8.3.12. Analysis by Region
8.3.13. Most Active Partners: Distribution by Number of Partnerships
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. AI in Oncology: List of Funding and Investment Analysis
9.3.1. Analysis by Year and Number of Funding Instances
9.3.2. Analysis by Year and Amount Invested
9.3.3 Analysis by Type of Funding and Number of Instances
9.3.4. Analysis by Year, Type of Funding and Amount Invested
9.3.5. Analysis by Type of Funding and Amount Invested
9.3.6. Analysis by Area of Application
9.3.7. Analysis by Focus Area
9.3.8. Analysis by Type of Cancer Indication
9.3.9. Analysis by Geography
9.3.10. Most Active Players by Number of Instances
9.3.11. Most Active Players by Amount Invested
9.3.12. Analysis by Type of Investors
9.3.13. Analysis by Lead Investors
9.4. Summary of Investments
9.5. Concluding Remarks
10. BLUE OCEAN STRATEGY: A STRATEGIC GUIDE FOR START-UPS TO ENTER INTO HIGHLY COMPETITIVE MARKET
10.1. Chapter Overview
10.2. Overview of Blue Ocean Strategy
10.2.1 Red Ocean
10.2.2 Blue Ocean
10.2.3 Comparison of Red Ocean Strategy and Blue Ocean Strategy
10.2.4. AI in Oncology: Blue Ocean Strategy and Shift Tools
10.2.4.1. Value Innovation
10.2.4.2. Strategy Canvas
10.2.4.3. Four Action Framework
10.2.4.4. Eliminate-Raise-Reduce-Create (ERRC) Grid
10.2.4.5. Six Path Framework
10.2.4.6. Pioneer-Migrator-Settler (PMS) Map
10.2.4.7. Three Tiers of Noncustomers
10.2.4.8. Sequence of Blue Ocean Strategy
10.2.4.9. Buyer Utility Map
10.2.4.10. The Price Corridor of the Mass
10.2.4.11. Four Hurdles to Strategy Execution
10.2.4.12. Tipping Point Leadership
10.2.4.13. Fair Process
10.3. Conclusion
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Artificial Intelligence in Oncology Market, 2022-2035
11.4. Artificial Intelligence in Oncology Market: Analysis by Type of Cancer, 2022-
2035
11.4.1. Artificial Intelligence in Oncology Market for Solid Malignancies, 2022-2035
11.4.2. Artificial Intelligence in Oncology Market for Breast Cancer, 2022-2035
11.4.3. Artificial Intelligence in Oncology Market for Lung Cancer, 2022-2035
11.4.4. Artificial Intelligence in Oncology Market for Prostate Cancer, 2022-2035
11.4.5. Artificial Intelligence in Oncology Market for Colorectal Cancer, 2022-2035
11.4.6. Artificial Intelligence in Oncology Market for Brain Tumor, 2022-2035
11.4.7. Artificial Intelligence in Oncology Market for Others, 2022-2035
11.5. Artificial Intelligence in Oncology Market: Analysis by Type of End-User, 2022-2035
11.5.1. Artificial Intelligence in Oncology Market for Hospitals, 2022-2035
11.5.2. Artificial Intelligence in Oncology Market for Pharma Companies, 2022-2035
11.5.3. Artificial Intelligence in Oncology Market for Research Institutes, 2022-2035
11.5.4. Artificial Intelligence in Oncology Market for Others, 2022-2035
11.6. Artificial Intelligence in Oncology Market: Analysis by Key Geographical
Regions, 2022-2035
11.6.1. Artificial Intelligence in Oncology Market for North America, 2022-2035
11.6.2. Artificial Intelligence in Oncology Market for Europe, 2022-2035
11.6.3. Artificial Intelligence in Oncology Market for Asia Pacific, 2022-2035
11.6.4. Artificial Intelligence in Oncology Market for Rest of the World, 2022-2035
12. CONCLUSION
12.1. Chapter Overview
12.2. Key Takeaways
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Enlitic
13.2.1. Company Snapshot
13.2.2. Interview Transcript: David Wilson (Vice President, Marketing and Communications)
13.3. Nucleai
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Emily Salerno (Commercial Strategy and Operations Lead)
13.4. Mirada Medical
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Jon DeVries (Chief Executive Officer)
13.5. CancerCenter.AI
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Piotr Krajewski (Chief Executive Officer)
13.6. Visiopharm
13.6.1 Company Snapshot
13.6.2 Interview Transcript: Christian Vestergaard Kaltoft (Chief Executive Officer)
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/ai-in-oncology-market.html
You may also be interested in the following titles:
Quantum Computing in Drug Discovery Services Market
You may also like to learn what our experts are sharing in Roots educational series:
CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
Comments